<< Clinical Data raises $47.4 million through public offering of shares | Quinnova Pharmaceuticals raises $17.4 million through Series B financing >>

Advaxis to enroll patients in Phase II clinical trial of cervical dysplasia following IRB approval

Published on October 28, 2009 at 10:26 AM · No Comments

Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) biotechnology company, has received approval from the New England Institutional Review Board (IRB) to enroll the first patient in a Phase II clinical trial of cervical dysplasia (cervical intraepithelial neoplasia or CIN).

The study will be a blinded, randomized comparison of ADXS11-001 versus placebo for the treatment of cervical dysplasia.

SOURCE Advaxis, Inc.,

9c2c98ae-7d48-4a83-bd73-6d0207da94a2|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Biopsy, Biotechnology, Cancer, Cervical Dysplasia, Cervical Intraepithelial Neoplasia, Dysplasia, Immunology, Listeria, Placebo, Vaccine

Maintaining ideal BMI reduces mortality risk in healthy non-smoking adults: StudyA study looking at deaths from any cause found that a body mass index (BMI) between 20.0 and 24.9 is...
FDA grants orphan drug designation for MultiStem stem cell therapyAthersys, Inc. announced today that MultiStem, Athersys' multipotent adult progenitor stem cell ther...
Clinical trial data of imetelstat in patients with breast cancer presented at ASCO annual meetingGeron Corporation today announced the presentation of data from the clinical trial of imetelstat (GR...
ThisCaringHome.org: Interactive web site for caregivers of Alzheimer'sIt is estimated that Alzheimer's disease affects 5.3 million Americans and that number is expected t...
Advisory Committee on Immunization Practices supports the permissive use of GARDASILMerck & Co., Inc. announced today that the U.S. Centers for Disease Control and Prevention’s (CDC’s)...
FDA grants Fast Track designation to Corthera's relaxin for treating acute heart failureCorthera Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Trac...
Less invasive approach for the treatment of cervical intraepithelial neoplasiaIn the United States alone, approximately three-and-a-half million women have abnormal Pap smear tes...
Natural mechanism for immune suppression may lead to new cancer drugsA natural mechanism pirated by tumors and HIV to evade the immune response is opening the door to be...
Investigational treatment for cervical dysplasiaTemple University Hospital's Center For Women's Health is participating in a national study to deter...
Finding foodborne illness outbreaks sooner, fasterIf 25 people eating at a single banquet hall became sick and needed hospitalization, determining the...

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Quirky Comment Title
Name*
E-mail*
Country Country flag

b i u quote

Comment
Preview

Leave this field blank

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.